Aldeyra Therapeutics (ALDX) vs. Microbot Medical (MBOT) Head-To-Head Comparison
Aldeyra Therapeutics (NASDAQ: ALDX) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Risk and Volatility
Aldeyra Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500.
This is a summary of current ratings for Aldeyra Therapeutics and Microbot Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aldeyra Therapeutics currently has a consensus price target of $19.40, indicating a potential upside of 198.46%. Given Aldeyra Therapeutics’ higher possible upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than Microbot Medical.
Insider & Institutional Ownership
48.0% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 4.7% of Microbot Medical shares are owned by institutional investors. 19.0% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 31.8% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Aldeyra Therapeutics and Microbot Medical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aldeyra Therapeutics||N/A||N/A||-$18.69 million||($1.41)||-4.61|
|Microbot Medical||$120,000.00||344.18||-$9.66 million||($0.69)||-1.55|
Microbot Medical has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
This table compares Aldeyra Therapeutics and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aldeyra Therapeutics beats Microbot Medical on 6 of the 10 factors compared between the two stocks.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
About Microbot Medical
Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.
Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.